InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,277.51
(
0.80%
)
US TECH 100
18,064.80
(
0.02%
)
Dow Jones
38,686.32
(
1.51%
)
Brent Oil
81.30
(
0.00%
)
Bitcoin
68,094.64
(
0.55%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

biotech_researcher

Send PM Follow Ignore
Followers 82
Posts 12460
Boards Moderated 0
Alias Born 07/25/2008

biotech_researcher

Re: None

Thursday, 09/15/2016 8:31:11 AM

Thursday, September 15, 2016 8:31:11 AM

Post# of 80490
The data presented today and especially the oral sessions this weekend should be very pivotal in the perception of Ponatinib going forward. And, it IS uncanny that I saw no PR on this before today. Some of this data had to be used in filing with the FDA of the label revisions. Wow. Who said Ponatinib was a dead end??
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up